세계의 헬스케어 나노기술(나노의학) 시장 규모 : 모달리티별, 적응증별, 용도별, 지역별 범위 및 예측

Healthcare Nanotechnology (Nanomedicine) Market Size And Forecast

Healthcare Nanotechnology (Nanomedicine) Market size was valued at USD 220.34 Billion in 2024 and is projected to reach USD 552.93 Billion by 2032, growing at a CAGR of 13.14% from 2026 to 2032.

The Global Healthcare Nanotechnology (Nanomedicine) Market is growing as the regulatory framework improves. Growth in technological developments, as well as an increase in research investment, will drive market expansion. COVID-19 has had a relatively good impact on the nanomedicine sector. This was attributable to a surge in the need for nanomedicines used to treat cancer-like disorders. Furthermore, market participants have seen a growth in spending on materials and resources as a result of an increase in nanomedicine R&D activities in all areas. The Global Healthcare Nanotechnology (Nanomedicine) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Healthcare Nanotechnology (Nanomedicine) Market Definition

Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs.

Preserving and improving human health helps in doing so. For various life-threatening diseases like orthopedic problems, diseases related to blood, lungs, cancer, Parkinson's, Alzheimer's, diabetes, neurological, and cardiovascular system Nanomedicine offers a strong solution. These are multifunctional drugs with programmable properties which help in finding the applications such as monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. Development of a replacement nanomedicine takes several years which is supported by various technologies like dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

Nanomedicine may be a promising mode of cancer treatment. This growing field of medical research is often wont to discover a better-personalized treatment for a good range of diseases, including cancer. As nanomedicine promises to develop innovative drugs which have greater efficacy and lesser side effects than standard therapies because of its benefits as it has the properties of matter at the nanoscale. The necessity for technological advancements to reinforce disease diagnosis, treatment, and prevention is thus found to be the main driver for the Healthcare Nanotechnology (Nanomedicine) Market. Within the case of cancers, nanomedicine offers promising changes from the present methods of diagnosing and treating cancer.

Global Healthcare Nanotechnology (Nanomedicine) Market Overview

Nanomedicines have the potential which can fully change or revolutionalize the current scenario of detection of disease, diagnosis, and treatment methods. With the emergence of innovative technologies such as drug delivery, and also there are several benefits of nanomedicine that will significantly boost the Global Healthcare Nanotechnology (Nanomedicine) Market. Rising government funding and support will lead to an increase in demand for the market as well as its safe and cost-effective therapies will support the market growth.

The increasing out-licensing of nano drugs and the growth of healthcare facilities in emerging economies help in creating an ample amount of opportunities for market growth. Technological advancements including relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic also as acute disorders are expected to bolster growth in this market. Nanotechnology involves The miniaturization of larger structures and chemicals at a nanometric scale involves Nanotechnology rapidly revolutionized drug administration, thus influencing the adoption of the technology.

Expected developments in nanorobotics due to the increase in funding from the govt organizations are expected to induce potential in the market. The potential pipeline of products supported by the nano molecules and associated technologies is anticipated to drive the market with potential avenues of growth. Utilization of DNA origami for healthcare applications driving the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. However, the long approval process and risks related to nanomedicine (environmental impacts) restrain the market growth.

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation Analysis

The Global Healthcare Nanotechnology (Nanomedicine) Market is segmented on the basis of Modality, Indication, Application, And Geography.

Healthcare Nanotechnology (Nanomedicine) Market, By Modality

• Treatment
• Diagnostics

Based on Disease, The market is bifurcated into Treatment and Diagnostics. The Treatment segment holds the largest market share among the others and is anticipated to stay dominant during the projected timeline, owing to technological breakthroughs in nanomedicines, increased nanomedicine adoption, rising chronic disease incidence rates, and an increase in the number of advanced and effective product launches.

Healthcare Nanotechnology (Nanomedicine) Market, By Indication

• Clinical oncology
• Infectious diseases
• Clinical cardiology
• Orthopedics
• Neurology
• Urology
• Ophthalmology
• Immunology
• Others

Based on Application, The market is bifurcated into Clinical oncology, Infectious diseases, Clinical cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others. The Clinical oncology category was the largest category contributing to the growing market and is expected to maintain its dominance during the projected timeline, owing to an increase in the number of oncology disorders and rising disposable income. In the subject of oncology, nanomedicine provides intriguing alternatives to current cancer treatment and diagnosis approaches. The use of nano-based cancer medicines and diagnostics has made significant progress, and numerous new breakthroughs are currently in the works. Nanobiotix, a clinical-stage nanomedicine company, received CE approval in April 2019 for Hensify (NBTXR3), which is an aqueous suspension of crystalline hafnium oxide or HfO2 nanoparticles intended for injection directly into the tumor prior to a patient's first classic radiation therapy treatment of advanced soft tissue sarcoma.

Healthcare Nanotechnology (Nanomedicine) Market, By Application

• Drug delivery
• Regenerative medicine
• Implants
• Diagnostic
• Imaging
• Vaccines
• Others

Based on Application, The market is bifurcated into Drug Delivery, Regenerative medicine, Implants, Diagnostic, Imaging, Vaccines, and Others. The Drug delivery sector was the largest contributor to the international market and is expected to persist dominant throughout the projected period, owing to a rise in the frequency of diseases like cancer and the COVID-19 virus, as well as a rise in awareness of the applications of nanomedicines.

Healthcare Nanotechnology (Nanomedicine) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Regional Analysis, The Global Healthcare Nanotechnology (Nanomedicine) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the maximum market share in this segment. The primary drivers driving market growth in the United States include technology improvements along with applicable applications in early illness detection, preventative intervention, and prevention of chronic and acute disorders, which are likely to drive market expansion. According to the CDC, heart disease accounted for one in every four fatalities in the United States in 2021. Coronary heart disease is the largest cause of death due to cardiac disease in the United States, accounting for 360,900 fatalities, and is followed by stroke (805,000). This high burden may result in a large need for particular therapeutic nano vectors, nanostructured stents, and tissue regeneration implants.
• Furthermore, various R&D efforts on nanotechnology-based medications and diagnostics are underway in the country, which may fuel market expansion. For instance, in January 2020, Stanford University researchers produced a medication coated with nanoparticles that slows the progression of atherosclerosis in rats by lowering plaque deposition in their arteries without generating negative side effects. However, Asia-Pacific is predicted to develop at the fastest rate over the forecast period. Furthermore, Japan and China are projected to grow at a rapid CAGR in the Asia-Pacific nanomedicine market, owing to improvements in healthcare infrastructure, an increase in the number of health facilities coupled with smart instruments, the development of the R&D sector, an increase in healthcare reforms, and adoption of advanced technologies of nanomedicines.

Key Players

The "Global Healthcare Nanotechnology (Nanomedicine) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services, Inc., Luminex Corporation, Merck & Company, Inc., Nanosphere, Inc., Bristol-Myers Squibb, Leadient BioSciences Inc., Teva Pharmaceutical Industries Ltd, Mallinckrodt plc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• January 2022 - NaNotics LLC has formed a research partnership with the Mayo Clinic to create a NaNot which addresses the soluble form of PD-LI, a tumor-generated immunological inhibitor.
• December 2021 - Acura NanoMedicine Inc has announced the development of a nanotechnology-based approach to reduce medication resistance and revitalize cancer treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY MODALITY

• 5.1 Overview
• 5.2 Treatment
• 5.3 Diagnostics

6 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY INDICATION

• 6.1 Overview
• 6.2 Clinical oncology
• 6.3 Infectious diseases
• 6.4 Clinical cardiology
• 6.5 Orthopedics
• 6.6 Neurology
• 6.7 Urology
• 6.8 Ophthalmology
• 6.9 Immunology
• 6.10 Others

7 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Drug delivery
• 7.3 Regenerative medicine
• 7.4 Implants
• 7.5 Diagnostic
• 7.6 Imaging
• 7.7 Vaccines
• 7.8 Others

8 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Sanofi SA
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Abbott
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Pfizer Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 CombiMatrix Corporation
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 GE Healthcare
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Celgene Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Johnson & Johnson Services, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Luminex Corporation
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Merck & Company, Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Nanosphere
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Nanosphere, Inc.
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Bristol-Myers Squibb
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.12 Leadient BioSciences Inc.
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Teva Pharmaceutical Industries Ltd
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Mallinckrodt plc.
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research